# Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

> **NCT05701774** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Soleno Therapeutics, Inc.** · enrollment: 83 (estimated)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** DCCR

## Key facts

- **NCT ID:** NCT05701774
- **Lead sponsor:** Soleno Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-31
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701774, "Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05701774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*